Article

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and Resistance

2026-07-14

Abstract excerpt

Antibody-drug conjugates (ADCs) have emerged as a powerful class of targeted therapeutics in many clinical areas, such as in oncology. Despite their efficacy, the onset of adverse events has been a major drawback in their clinical use. Among other explanations, the clinical performance of the ADCs has been associated with the chemistry of the linker connecting antibody and payload. Linkers determine plasma stabili...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 75df9e82-2d16-5b60-bce6-bc8b46d42a03
DOI: 10.20944/preprints202607.0932.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceDOI 10.20944/preprints202607.0932.v1Read

Current ADC Linker ChemistrySemantic proximity Read

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsSemantic proximity Read

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Semantic proximity Read

Antibody-mediated co-delivery of programmable drug combinationsSemantic proximity Read

Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.Semantic proximity Read

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read

PROxAb Shuttle: A non-covalent plug-and-play platform for the rapid generation of tumor-targeting antibody-PROTAC conjugatesSemantic proximity Read

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacySemantic proximity Read

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates LibrarySemantic proximity Read

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design PerspectiveSemantic proximity Read